Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.99 USD
-0.15 (-0.31%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $48.98 -0.01 (-0.02%) 4:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BMY 48.99 -0.15(-0.31%)
Will BMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
Other News for BMY
ketteQ Appoints Chris Gaffney to Executive Advisory Board
S&P 500 stocks with biggest estimated EPS declines for Q1
Baron Health Care Fund Q1 2024 Shareholder Letter
Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
Bristol-Myers inks USD380 million supply agreement with Cellares